NCT02807987View on ClinicalTrials.gov

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 15, 2017

Study Completion Date

May 15, 2017

Conditions
Hypertension With Moderate Renal Impairment
Interventions
DRUG

CS-3150

CS-3150 1.25 to 2.5, 5mg, orally

Trial Locations (1)

Unknown

Nagano

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY